🇺🇸 FDA
Patent

US 7795389

Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins

granted A61KA61K38/00

Quick answer

US patent 7795389 (Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins) held by The Board of Regents of the University of Texas System expires Mon Sep 09 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Sep 14 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 09 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K38/00